Grace is one of the world's leading specialty chemicals and materials companies with employees located in more than 40 countries.
More Press Releases >
Apr 02, 2014|
Grace Announces Release Date for First Quarter 2014 Results
W. R. Grace & Co. (NYSE: GRA) announced today that it will release its
first quarter 2014 financial results at 6:00 a.m. ET on Wednesday, April
23, 2014. A company-hosted conference call and webcast will follow at
11:00 a.m. ET that day.
Mar 24, 2014|
Grace Introduces Disposable Purification Solution to Lower Cost and Accelerate Drug Development For Biotech
W. R. Grace & Co. (NYSE: GRA) has introduced ProVance™ pre-packed
columns, a portfolio of products for cost-effective purification of
biologic drugs, specifically monoclonal antibodies (mAbs). Monoclonal
antibodies are key therapeutic agents used to treat rheumatoid
arthritis, cancer and other diseases. Currently in the U.S., mAbs
constitute the single largest biologics product category in the clinical
Mar 19, 2014|
Grace Announces Five-Year Financial Framework; Sets $2 Billion Adjusted Free Cash Flow Target
W. R. Grace & Co. (NYSE: GRA) announced that the company will provide a
five-year financial framework for growth and shareholder returns at its
investor day, to be held today in New York City. This framework will
provide investors with the company’s long-term view on sales, earnings
and cash flow growth, capital allocation, and shareholder returns.
Mar 06, 2014|
Grace to Host Investor Day March 19 in New York City
W. R. Grace & Co. (NYSE: GRA) will conduct an investor day for
institutional investors and analysts on Wednesday, March 19, 2014, in
New York City. Fred E. Festa, chairman and chief executive officer,
together with other members of the company’s senior management team,
will provide updates on key business strategies and growth initiatives.
Feb 05, 2014|
Grace Reports Fourth Quarter 2013 Adjusted EPS of $1.09 and Provides 2014 Earnings Outlook
W. R. Grace & Co. (NYSE: GRA) announced fourth quarter net
income of $29.7 million, or $0.38 per diluted share, compared with a net
loss for the prior-year quarter of $184.3 million, or $2.44 per diluted
share. Both quarters included charges related to the company’s
asbestos-related liability and bankruptcy proceedings. Adjusted EPS for
the 2013 fourth quarter was $1.09 per diluted share compared with $1.21
per diluted share for the prior-year quarter.